WO2008109382A8 - Nucleic acid compounds for inhibiting pkn3 gene expression and uses thereof - Google Patents

Nucleic acid compounds for inhibiting pkn3 gene expression and uses thereof Download PDF

Info

Publication number
WO2008109382A8
WO2008109382A8 PCT/US2008/055386 US2008055386W WO2008109382A8 WO 2008109382 A8 WO2008109382 A8 WO 2008109382A8 US 2008055386 W US2008055386 W US 2008055386W WO 2008109382 A8 WO2008109382 A8 WO 2008109382A8
Authority
WO
WIPO (PCT)
Prior art keywords
pkn3
nucleic acid
gene expression
inhibiting
acid compounds
Prior art date
Application number
PCT/US2008/055386
Other languages
French (fr)
Other versions
WO2008109382A1 (en
WO2008109382B1 (en
Inventor
Steven C Quay
James Mcswiggen
Narendra K Vaish
Mohammad Ahmadian
Original Assignee
Mdrna Inc
Steven C Quay
James Mcswiggen
Narendra K Vaish
Mohammad Ahmadian
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mdrna Inc, Steven C Quay, James Mcswiggen, Narendra K Vaish, Mohammad Ahmadian filed Critical Mdrna Inc
Publication of WO2008109382A1 publication Critical patent/WO2008109382A1/en
Publication of WO2008109382B1 publication Critical patent/WO2008109382B1/en
Publication of WO2008109382A8 publication Critical patent/WO2008109382A8/en
Priority to US12/552,082 priority Critical patent/US20100105134A1/en
Priority to US13/327,545 priority patent/US20130011922A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Abstract

The present disclosure provides meroduplex ribonucleic acid molecules (mdRNA) capable of decreasing or silencing PKN3 gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to a PKN3 mRNA. In addition, the meroduplex may have at least one uridine substituted with a 5-methyluridine, a nucleoside replaced with a locked nucleic acid, or optionally other modifications, and any combination thereof. Also provided are methods of decreasing expression of a PKN3 gene in a cell or in a subject to treat a PKN3-related disease.
PCT/US2008/055386 2007-03-02 2008-02-28 Nucleic acid compounds for inhibiting pkn3 gene expression and uses thereof WO2008109382A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US12/552,082 US20100105134A1 (en) 2007-03-02 2009-09-01 Nucleic acid compounds for inhibiting gene expression and uses thereof
US13/327,545 US20130011922A1 (en) 2007-03-02 2011-12-15 Nucleic acid compounds for inhibiting gene expression and uses thereof

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US93494007P 2007-03-02 2007-03-02
US60/934,940 2007-03-02
US93493007P 2007-03-16 2007-03-16
US60/934,930 2007-03-16
US97041407P 2007-09-06 2007-09-06
US60/970,414 2007-09-06

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/055382 Continuation-In-Part WO2008109379A1 (en) 2007-03-02 2008-02-28 Nucleic acid compounds for inhibiting il17a gene expression and uses thereof

Related Child Applications (3)

Application Number Title Priority Date Filing Date
PCT/US2008/055385 Continuation-In-Part WO2008109381A2 (en) 2007-03-02 2008-02-28 Nucleic acid compounds for inhibiting hif1a gene expression and uses thereof
AU2009212920A Division AU2009212920A1 (en) 2007-03-02 2009-09-01 Nucleic acid compounds for inhibiting gene expression and uses thereof
US12/552,082 Continuation-In-Part US20100105134A1 (en) 2007-03-02 2009-09-01 Nucleic acid compounds for inhibiting gene expression and uses thereof

Publications (3)

Publication Number Publication Date
WO2008109382A1 WO2008109382A1 (en) 2008-09-12
WO2008109382B1 WO2008109382B1 (en) 2008-11-20
WO2008109382A8 true WO2008109382A8 (en) 2009-08-06

Family

ID=39473614

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/055386 WO2008109382A1 (en) 2007-03-02 2008-02-28 Nucleic acid compounds for inhibiting pkn3 gene expression and uses thereof

Country Status (1)

Country Link
WO (1) WO2008109382A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2498821C1 (en) * 2012-04-10 2013-11-20 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Новосибирский национальный исследовательский государственный университет" (Новосибирский государственный университет, НГУ) Method for stimulating endogenous production of cytokines and hemopoietins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL166718A0 (en) * 2002-08-14 2006-01-15 Atugen Ag Further use of protein kinase n beta
US20050136437A1 (en) * 2003-08-25 2005-06-23 Nastech Pharmaceutical Company Inc. Nanoparticles for delivery of nucleic acids and stable double-stranded RNA
EP1942943A2 (en) * 2005-11-04 2008-07-16 Nastech Pharmaceutical Company Inc. Peptide-dicer substrate rna conjugates as delivery vehicles for sirna
CA2644347C (en) * 2006-03-23 2017-05-30 Santaris Pharma A/S Small internally segmented interfering rna
JP5876637B2 (en) * 2006-10-18 2016-03-02 マリーナ バイオテック，インコーポレイテッド Nicked or gapped nucleic acid molecules and their use

Also Published As

Publication number Publication date
WO2008109382A1 (en) 2008-09-12
WO2008109382B1 (en) 2008-11-20

Similar Documents

Publication Publication Date Title
WO2008109465A3 (en) Nucleic acid compounds for inhibiting fgfr gene expression and uses thereof
WO2008109381A3 (en) Nucleic acid compounds for inhibiting hif1a gene expression and uses thereof
WO2009029293A3 (en) Nucleic acid compounds for inhibiting myc gene expression and uses thereof
WO2010017319A3 (en) Nucleic acid compounds for inhibiting plk1 gene expression and uses thereof
WO2007128477A3 (en) SHORT INTERFERING RIBONUCLEIC ACID (siRNA) FOR ORAL ADMINISTRATION
WO2008109516A3 (en) Nucleic acid compounds for inhibiting ras gene expression and uses thereof
WO2008109352A8 (en) Nucleic acid compounds for inhibiting akt gene expression and uses thereof
WO2010006973A3 (en) Compositions and methods for inhibiting expression of tgf-beta receptor genes
WO2010017311A3 (en) Nucleic acid compounds for inhibiting birc5 gene expression and uses thereof
WO2007137220A3 (en) Compositions and methods for inhibiting expression of ikk-b gene
WO2008109375A3 (en) Nucleic acid compounds for inhibiting pik3c gene expression and uses thereof
WO2008109350A3 (en) Nucleic acid compounds for inhibiting il6 gene expression and uses thereof
WO2008109372A3 (en) Nucleic acid compounds for inhibiting pdgf gene expression and uses thereof
WO2008109548A3 (en) Nucleic acid compounds for inhibiting tgfb gene expression and uses thereof
WO2008109506A8 (en) Nucleic acid compounds for inhibiting jun gene expression and uses thereof
WO2008109443A3 (en) Nucleic acid compounds for inhibiting cdk2 gene expression and uses thereof
WO2008109546A3 (en) Nucleic acid compounds for inhibiting tgfbr gene expression and uses thereof
WO2011139843A3 (en) Multi-sirna compositions for reducing gene expression
WO2008109558A3 (en) Nucleic acid compounds for inhibiting tlr gene expression and uses thereof
WO2008109366A3 (en) Nucleic acid compounds for inhibiting ccnd1 gene expression and uses thereof
WO2008109487A3 (en) Nucleic acid compounds for inhibiting mme gene expression and uses thereof
WO2008109495A3 (en) Nucleic acid compounds for inhibiting cd40 gene expression and uses thereof
WO2008109364A3 (en) Nucleic acid compounds for inhibiting frap1 gene expression and uses thereof
WO2008109493A3 (en) Nucleic acid compounds for inhibiting cd19 gene expression and uses thereof
WO2008109368A3 (en) Nucleic acid compounds for inhibiting vegfr gene expression and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08731040

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08731040

Country of ref document: EP

Kind code of ref document: A1